申万菱信中证申万医药生物指数(LOF)C(015176)财务指标
| |
2025-12-31 |
2025-06-30 |
2024-12-31 |
2024-06-30 |
| 本期已实现收益 |
-790,085.90 |
-198,354.37 |
-2,000,312.29 |
-1,712,231.97 |
| 本期利润 |
2,294,546.55 |
1,523,255.47 |
-4,116,490.91 |
-6,483,477.09 |
| 加权平均基金份额本期利润 |
0.05 |
0.03 |
-0.09 |
-0.13 |
| 本期加权平均净值利润率(%) |
8.03 |
5.43 |
-13.92 |
-21.16 |
| 本期基金份额净值增长率(%) |
7.00 |
5.05 |
-12.50 |
-18.44 |
| 期末可供分配利润 |
-15,711,147.33 |
-15,870,235.37 |
-17,344,420.88 |
-21,206,915.05 |
| 期末可供分配基金份额利润 |
-0.35 |
-0.36 |
-0.39 |
-0.43 |
| 期末基金资产净值 |
29,565,340.49 |
28,346,901.56 |
27,160,339.54 |
27,982,105.07 |
| 期末基金份额净值 |
0.65 |
0.64 |
0.61 |
0.57 |
| 基金份额累计净值增长率(%) |
-19.22 |
-20.70 |
-24.51 |
-29.63 |